Background: Potential drug-drug interactions (PDDIs) might expand with new combination antiretroviral therapies (ART) and polypharmacy related to increasing age and comorbidities. We investigated the prevalence of comedications and PDDIs within a large HIV cohort, and their effect on ART efficacy and tolerability. Methods: All medications were prospectively recorded in 1,497 ART-treated patients and screened for PDDIs using a customized version of the Liverpool drug interactions database. Antiretroviral therapy (ART) has significantly reduced morbidity and mortality, thus improving long-term survival in HIV-infected individuals [1,2]. As a result, patients are more exposed to age-, disease-or treatment-related morbidities leading to polypharmacy and, consequently, to potential drug-drug interactions (PDDIs) [3] . Antiretroviral (ARV) agents are among the therapeutic agents with the highest potential for drug-drug interactions.
Introduction
drug absorption [8] . The risk for PDDIs can be further exacerbated by the use of over-the-counter drugs, herbal therapies and social/recreational drugs, which might not be reported to the physician [9] . Incomplete medication history also occurs because HIV-infected individuals might receive prescription drugs for other conditions from different healthcare providers [10] .
Drug interactions might be associated with a substantial risk for toxicity, decreased efficacy and subsequent emergence of drug resistance; therefore, the prevention, identification and management of drug interactions are crucial for patient care. The clinical effect of dose adjustments to manage ARV drug interactions was evaluated within the Ontario HIV Cohort Study and, interestingly, was associated with a larger reduction in HIV viral load as compared with unadjusted treatments [11] . Previous studies have indicated that PDDIs in HIV therapy are common, ranging from 23-41% [12] [13] [14] [15] ; however, those studies were performed retrospectively by medical chart or pharmacy record reviews, and thus might have underestimated the prevalence of PDDIs as the complete medication history is not always thoroughly documented [9, 10] . Furthermore, some of these studies were carried out with relatively small patient populations, and thus might reflect neither general prescribing patterns nor provide a complete description of PDDIs related to HIV therapy.
We prospectively investigated the prevalence of drug interactions associated with ARV agents among the participants of the Swiss HIV Cohort Study (SHCS). We then informed clinicians about PDDIs and analysed the medical management of deleterious interactions. Furthermore, we assessed risk factors for drug interactions and explored the association between PDDIs and viral suppression, as well as ART modification in the follow-up investigation.
Methods

Study population
This study included ART-treated patients from the SHCS, a nationwide prospective cohort study enrolling HIV-infected individuals aged ≥16 years, who were followed-up in HIV clinics or specialized HIV practices [16] . Socio-demographic characteristics, data on the clinical course, coinfection with HBV and HCV, ART, comedications (prophylaxis and treatment of opportunistic infections or cardiovascular drugs), reasons for ART modification (for example, viral failure, toxicity, patient's decision and physician's decision), immunological and viral parameters were collected on standardized forms at enrolment into the study and every 6 months thereafter (follow-up visits). The study was approved by the local ethical review boards and written informed consent was obtained from all participants.
Study design
All ART-treated patients scheduled for a follow-up visit from April 2008 to January 2009 were prospectively included in this study ( Figure 1 ). In addition to the regular clinical assessment, information on current medication was obtained by patient self-report and medical prescription history. The drugs documented included ART, comedications used for opportunistic infections and concurrent diseases, as well as medications used for symptomatic relief, herbals and recreational drugs. The complete treatment was subsequently screened for PDDIs using a customized version of the University of Liverpool drug interaction database [17] and, additionally, by two experts in HIV pharmacology. The Liverpool drug interaction database features interactive charts for assessing the risk of drug interactions between HIV-HIV drugs and HIV-non-HIV drugs. These charts categorized the severity of an interaction by using flags: a red flag for drugs that should not be coadministered as they might lead to serious adverse events or profoundly impair ART efficacy, an orange flag indicates a potential interaction that might require dosage modification or close monitoring to minimize clinical consequences and a green flag represents no known or anticipated interaction. Information on drug interactions for the medications not listed in the database was obtained from prescribing information, published studies or predicted on the basis of the metabolic pathway. These new data were subsequently implemented in the Liverpool database, for example, recent data have shown that ginkgo (Ginkgo biloba) and hops (Humulus lupulus) induce CYP450 expression via pregnane X receptor activation [18, 19] . PDDIs were independently validated by two experts (CM and SG) in HIV pharmacology according to the definitions described below and subsequently reported to the clinicians. The report provided a summary of the PDDIs as well as a recommendation for the management of PDDIs (efficacy or toxicity monitoring or dose adjustment). In order to investigate the adherence to our recommendations, medical feedback was requested for deleterious drug interactions, for example, red-flag interactions and orange-flag interactions that could have lowered the ARV drug level. Clinicians were asked in a structured questionnaire whether the drug causing the drug interaction was changed, or to provide a reason for not modifying the treatment (including, absence of side effects, viral load not affected, target ARV level documented by therapeutic drug monitoring, no alternative treatment available and drug interaction considered as irrelevant). The virological and immunological outcomes, as well as the rate of treatment discontinuation because of viral failure or drug tolerability, were assessed after 6-12 months using the SHCS database.
Definitions
Potentially clinically relevant drug interactions were considered as drug interactions requiring dose adjustment or contraindicated drug combinations according to the US Prescribing Information and/or the European Summary of Product Characteristics [20, 21] . Drug interactions were not counted as clinically significant if the appropriate dose adaptation had already been performed (for example, reduced dose of didanosine with tenofovir disoproxil fumarate [TDF] or atorvastatin in the presence of a boosted PI), if the change in pharmacokinetic parameters was <25%, if the interaction was reported as clinically irrelevant or if the level of evidence was judged as very low by the expert in HIV pharmacology. Finally, for the determination of the number of PDDIs, ritonavir was not counted as a separate ARV when prescribed as a boosting agent. Viral suppression was defined as an HIV viral load <50 copies/ml at the time of comedication assessment and after 6-12 months of follow-up.
Statistical analyses
Basic socio-demographic characteristics, CD4 + T-cell count, HIV viral load, ART regimens and comedication were compared using the χ 2 test or Fisher's exact test for categorical variables, and the Mann-Whitney U test for continuous variables. Logistic regression was used to investigate factors associated with having a comedication and, in these patients, predictors of PDDIs. All analyses were performed using Stata software version 9.2 (Stata Corp., College Station, TX, USA) for Windows.
Results
Study population and their medications
Medical prescriptions were analysed for 1,497 ARTtreated patients (median age 46 years, interquartile range [IQR] 40-52; 67% male and 81% White). Current illicit drug use was reported by 264 individuals, of whom 51 were currently injecting drug users. Coinfection with HBV and HCV was found in 5% and 26% of the study population, respectively. The median CD4 + T-cell count was 505 cells/mm 3 (IQR 357-689) and viral suppression (<50 copies/ml) was noted in 85% of the whole study population, and in 87% of 978 patients receiving ART for at least 6 months. Overall, ART regimens were mainly PI-(46%) or NNRTI-based (38%) with TDF plus emtricitabine as the nucleoside reverse transcriptase inhibitor (NRTI; 45%) backbone. The most frequently administered PIs were boosted lopinavir (LPV; 26%) and boosted atazanavir (ATV; 22%), whereas efavirenz (EFV; 33%) was the most prescribed NNRTI. Overall, 68% (1,013/1,497) of participants had ≥1 comedication ( Figure 1 ). The list of comedications, including prescription and over-the-counter drugs, is shown in Figure 2 . The two most commonly prescribed therapeutic classes were cardiovascular and central nervous system (CNS) drugs, taken by 56% and 31% of the patients, respectively. Overall, the consumption of over-the-counter drugs, as well as the use of herbals, was relatively low as compared with prescription drugs. The use of a specific therapeutic class was correlated with socio-demographic factors; thus, analgesics and hormones were more often prescribed to women (20% [women] 
Prevalence, characteristics and effect of the identified potential drug-drug interactions
Overall, 40% (599/1,497) of patients had ≥1 PDDI (1 PDDI, 2 PDDIs and 3 PDDIs in 54%, 24% and 12% of patients, respectively; a maximum of 11 PDDIs were observed in two individuals). The characteristics of the patients treated with ART and a comedication according to the presence or absence of PDDIs are depicted in Table 1 .
Red-flag and orange-flag interactions were found in 2% (21/1,013) and 59% (597/1,013) of participants with comedication, respectively ( Figure 1 ). Red-flag interactions included mainly the coadministration of PIs or EFV with midazolam, whereas orange-flag interactions involved predominantly EFV (26%), boosted LPV (22%) and boosted ATV (21%) with CNS drugs (49%), cardiovascular agents (34%) and methadone (19%; Table 2 ). Interactions between HIV-HIV drugs were detected in 3% (28/1,013) of patients with comedication and were essentially characterized by the coadministration of unboosted ATV with nevirapine (NVP) or TDF ( Table 2 ). PDDIs that could have lowered the HIV drug concentration and/or impaired viral suppression were found in 4% (41/1,013) of patients with comedication. Such interactions included nelfinavir or ATV plus esomeprazole, ATV plus NVP, ATV plus TDF, fosamprenavir plus LPV, EFV plus LPV, EFV plus rifampin, EFV plus ginkgo, EFV or ATV plus hops, ATV plus ranitidine and the combination abacavir (ABC)/lamivudine (3TC)/TDF with no PIs or NNRTIs. Overall, two identified drug interactions were pharmacodynamic in nature and resulted in potentially additive toxicities (that is, didanosine The bars represent the percentage of patients using one or more drugs of the corresponding therapeutic class. Cardiovascular drugs included antilipidemics (16%), antiplatelets/anticoagulants (9%), angiotensin converting enzyme inhibitors (8%), β-blockers (6%), diuretics (5%), angiotensin II inhibitors (5%), insulin/antidiabetics (4%) and calcium channel inhibitors (3%). Central nervous system (CNS) agents included anxiolytics/sedatives (13%), antidepressants (12%), antipsychotics (3%) and anticonvulsants (3%). Anti-infectives included antibacterials (6%), antivirals (3%), antifungals (2%) and antimycobacterials (2%). Analgesics included anti-inflammatory drugs (5%), paracetamol (4%) and narcotic analgesics (2%). Gastrointestinal drugs included proton pump inhibitors (7%), antidiarrheals (3%) and H 2 blockers (1%). A red flag indicates drugs that should not be coadministered as they might lead to serious adverse events or profoundly impair antiretroviral therapy efficacy. An orange flag indicates a potential interaction that might require dosage modification or close monitoring to minimize clinical consequences. A green flag represents no known or anticipated interaction. The percentage of patients with red-flag, orange-flag and green-flag interactions among the 1,497 participants are represented with different shades in the corresponding therapeutic class.
plus stavudine and zidovudine plus ribavirin). With the exception of the ABC/3TC/TDF combination, the remaining drug interactions were pharmacokinetic in nature and included potential alteration of absorption (that is, nelfinavir or ATV plus esomeprazole, and ATV plus ranitidine), decrease in renal excretion (that is, TDF plus valaciclovir) and predominantly inhibition or induction of CYP450.
Factors associated with the presence of a comedication and potential drug-drug interactions
In the multivariate analyses, after adjustment for sociodemographic and HIV-related variables, advanced age, female gender, obesity and coinfection with HCV were independently associated with a higher risk of having a comedication. By contrast, higher CD4 + T-cell count and triple-NRTI regimens were associated with a lower risk (Table 3) .
Among patients with comedication, independent risk factors for PDDIs were current illicit drug use, coinfection with HCV, complex ART regimen and ≥2 comedications in a multivariate analysis, adjusted as previously (Table 4) . After additional adjustment for the most frequent comedications, higher risk of PDDIs was observed in individuals receiving a complex ART regimen, ≥2 comedications and those treated with CNS drugs and methadone, suggesting that the association between PDDIs and HCV or current illicit drug use was explained by the higher use of CNS drugs and methadone in these patients. 
Medical management of potential deleterious drug-drug interactions
Overall, 60 patients had a red flag and/or PDDIs that could have altered ARV drug levels. The medical management of these PDDIs, after informing the physician and providing recommendations, is shown in Table 5 . The overall adherence to our recommendations was 38%. The medical decision for not modifying or monitoring a treatment when suggested was essentially motivated by clinical observations, such as maintenance of the viral suppression and absence of side effects. In a few patients, midazolam had to be maintained because of the patient's addiction to this drug.
Outcome at 6-12 months
At the time of comedication assessment, viral suppression was noted in 84.5% of patients with PDDIs compared with 86.4% without PDDIs (P=0.386), and was observed in 87.3% versus 88.2%, respectively, after 6-12 months of follow-up (P=0.685). In a subgroup analysis, we compared patients with PDDIs likely to be associated with virological failure (n=41) with patients with PDDIs that do not lower ARV drug concentrations (n=560). In this analysis, a similar outcome was documented (88% of patients with PDDIs lowering ARV versus 84% of patients with PDDIs not lowering ARV had virological suppression <50% copies/ml, respectively) after 6-12 months of follow-up (P=0.554). (P=0.774). Treatment change because of viral failure occurred in 7% of patients with PDDIs versus 5% without PDDIs (P=0.517).
Discussion
PDDIs in HIV therapy are increasing with more complex ART and associated comorbidities. No adverse effects were noted on ART efficacy or tolerability in a large HIV cohort; however, PDDIs were primarily related to the ARV acting on the comedication. The majority of identified PDDIs occurred between PI-or NNRTI-and CNS-(49%) or cardiovascular (34%) drugs, the two most prescribed therapeutic classes among our study population. The high proportion of CNS drugs is explained by the fact that individuals with psychiatric illness, including substance abuse, represent a considerable part of the HIV-infected population [22] . Cardiovascular drugs result from the ageing HIV population and the increased risk for cardiovascular diseases associated with ART itself and possibly HIV [23] . For the major part, PDDIs were orange-flag interactions requiring a potential dose adjustment or close monitoring to minimize clinical consequences. Only 2% of the drug combinations were contraindicated and only 4% could have lowered the ARV drug concentration. There was no evidence that ART efficacy was compromised. The limited number of patients with deleterious interactions probably reflects the expert care in HIV clinics with specialized physicians and nurses, but does not exclude that PDDIs might be more frequent in non-HIV settings. Other factors might also have played a role in limiting interactions, such as the use of web-based HIV drug interaction databases by the physicians, as well as the consultation with clinical pharmacologists or pharmacists and the rather low reported use of nonprescription drugs in our population. The analysis of the medical management of deleterious interactions suggests that the introduction of interaction alert systems could possibly anticipate interactions and further improve the quality of prescribing. In our study, the pharmacological advice was provided after initiating the drug combination, which was thereafter maintained in absence of adverse clinical outcome. Knowledge of the risk factors for PDDIs might help clinicians prevent drug interactions. Risk factors that were independently associated with PDDIs included more complex ART regimens, generally administered after viral resistance has developed, and the presence of methadone or CNS agents, which were more often used by patients with substance abuse and/or with HCV infection in our study. The recognition of these factors should promote particular attention in terms of drug prescription and drug interaction screening. As expected, the risk for PDDIs increased with the number of comedications. Polypharmacy was more frequent in older or obese patients as a consequence of increased risk for cardiovascular diseases [3] , and in patients with HCV infection because of a higher incidence of opportunistic infections or substance abuse in this particular population [24, 25] . Also, gender differences in the consumption of prescription and over-the-counter drugs have been previously reported in another HIV-infected population study [9] . For instance, the use of analgesics was shown to be more frequent in women, which is consistent with our observation.
Online drug interactions databases are valuable tools in clinical practice; however, these databases have several limitations that include discrepancies between databases [26] , their reliability is highly dependent on timely updates and the clinical relevance of PDDIs cannot be precisely predicted or extrapolated. The latter limitation relies upon the fact that the database describes drug interactions between two compounds, whereas HIV therapy often combines multiple drugs that will mutually interact. Also, some interactions are not recognized until the publication of case reports as they imply new mechanisms, for example, the interaction between rosuvastatin and LPV occurs possibly through the hepatic influx transporter OATP1B1 [27] ; therefore, physicians are encouraged to consult clinical pharmacologists or pharmacists for complex regimens or drug combinations with limited data.
The use of external databases for checking drug-drug interactions is of particular value in developing countries where the risk of PDDI is increased because of a higher incidence of coinfections, such as tuberculosis, and because of the limited access to ARV therapeutic drug monitoring. However, the management of PDDIs in resource-poor settings is problematic because of the lack of affordable alternative treatments and the use of fixed-dose formulations for ARV [28] . Drug interaction studies between combination ART and agents used in resource-limited settings, and the establishment of protocols for treatment of coinfection taking into account local drug availability, are urgently needed.
Some limitations of our study should be acknowledged. The ARV plasma levels were available only in a minority of participants with comedication and the dose or eventual dose adjustment of the comedications was not systematically reported; thus, clinicians might have been aware of interactions but decided to prescribe potentially interactive drugs with adjusted dose or under close monitoring as their benefit exceeded their harm. As a result, the percentage of PDDIs might have been overestimated. Another limitation resides in the fact that a potential drug interaction might not always turn into an actual drug interaction in a given person because of the large interindividual variability in drug disposition that can be partly explained by genetic variations in CYP450 or drug transporters. The gap between potential and actual drug interactions might also reflect the degree of evidence used to categorize the severity of an interaction. To limit this issue, the Liverpool drug interaction database is moving towards the GRADE system of quality of evidence and strength of recommendation [29] . Toxicities in relation to interactions leading to increased drug levels of the ARV or comedication were not specifically assessed using a detailed questionnaire as the study was not designed for that purpose. However, the analysis of ART modification provided an indirect measure of the toxicity as treatment changes can be motivated by clinical or serious laboratory adverse events. Several strengths should be noted. The large population, as well as the multicentre and prospective design, provide valuable data on PDDIs as it reflects the general prescribing patterns and documents an individual's complete drug regimen, although we cannot fully exclude under-reporting bias. Finally, participants were followed-up for the consequences of PDDIs on ART response and tolerability.
In summary, potentially clinically relevant drug interactions have become a major issue in HIV therapy because of the ageing HIV population and increasing prevalence of comorbidities; however, the majority are manageable if particular attention is paid to select the most appropriate and least interactive drug, and if dose adjustments or monitoring are made accordingly. For that purpose, clinician's self-education about interacting drugs, the knowledge of a patient's complete drug regimen and the risk factors associated with PDDIs are crucial to prevent, recognize and manage unwanted pharmacological effects.
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